Pfizer (PFE) Other Working Capital Changes (2009 - 2026)

Pfizer has disclosed Other Working Capital Changes across 18 years of filings, most recently posting $1.7 billion for Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 9.74% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 109.99% YoY), while the FY2025 annual figure was -$1.3 billion, up 61.86% from the prior year.
• Other Working Capital Changes rose to $1.7 billion in Q1 2026, from -$8.2 billion in the prior quarter.
• Over the last five years, Other Working Capital Changes for PFE reached as high as $8.1 billion in Q4 2022 and fell as low as -$10.0 billion in Q4 2023.
• The 5-year median for Other Working Capital Changes is $2.8 billion (2022), against an average of $1.7 billion.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes jumped 654.38% — and 2025, when it sank 99.4%.
• A 5-year view of Other Working Capital Changes shows it stood at $8.1 billion in 2022, then tumbled by 223.24% to -$10.0 billion in 2023, then soared by 160.17% to $6.0 billion in 2024, then tumbled by 237.4% to -$8.2 billion in 2025, then jumped by 121.04% to $1.7 billion in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $1.7 billion, -$8.2 billion, and $36.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.